This review summarizes the existing evidence for potential non-ventilatordependent strategies to prevent or ameliorate bronchopulmonary dysplasia (BPD). Oxygen plays an important pathogenetic and therapeutic role for BPD. Targeting infants with lower saturation of peripheral oxygen levels than traditionally used seems justified. Inhaled nitric oxide has not proven effective on pulmonary outcome in extremely low birth weight infants. Diuretics can ameliorate lung function transiently. High intramuscular doses of vitamin A reduce the risk of BPD. Prophylactic application of natural surfactant may also confer benefits. Recently, early administration of caffeine has been shown to decrease risk of BPD. However, assessment of long-term effects is needed before routine use can be recommended. Owing to potential short-and long-term effects, postnatal corticosteroids should be restricted to the most severe manifestations of BPD. Superoxide dismutase and a1-proteinase inhibitor have not shown efficacy in preventing BPD. The potential role of anti-inflammatory therapies like Clara Cell 10 kDa protein has yet to be defined.
Introduction
Advances in perinatal and neonatal medicine including prenatal steroids and surfactant therapy for respiratory distress syndrome have significantly improved survival of extremely preterm infants over the last two decades. However, they have not led to a substantial reduction in the incidence of bronchopulmonary dysplasia (BPD). 1 Our insights into the pathogenesis and epidemiology of BPD have expanded considerably. 2, 3 Nonetheless, most of the therapies used in the management of infants with this disease are still not evidence-based. 4 In this review, we discuss the existing evidence for a number of potential non-ventilatordependent strategies to prevent or ameliorate BPD (Figure 1 ).
Oxygen therapy
Although oxygen therapy is one of the mainstays in the management of infants at high risk for or with established BPD, there is no consensus about the level of oxygen saturation below which supplemental oxygen should be administered. 5 Oxidative stress in the initial phase of life has clearly been linked to the development of BPD. 6 Recent data on resuscitation of term newborns with 100% oxygen suggest that even short periods of hyperoxemia in early life can lead to prolonged oxidative stress in this patient group. 7 Preterm infants with their reduced intracellular antioxidative defense may have a high risk of suffering from potential detrimental effects of relative hyperoxemia in the first weeks of life. It has been shown that even short periods of such relative hyperoxemia immediately after birth can lead to a prolonged cerebral vasoconstriction in this group of patients. 8 Tin et al. 9 found in a retrospective observational study that infants <27 weeks gestational age, who were kept at an SpO 2 level of 70 to 90% in the first 8 weeks of life, were ventilated for a shorter time and were less likely to need supplemental oxygen at 36 weeks of postmenstrual age than infants who were given supplemental oxygen to maintain an SpO 2 of 88 to 98%. There was no significant difference in survival or rate of cerebral palsy at the age of one year between the groups. As long as data from larger randomized, prospective trials are missing, the results of Tin's study have to be taken into account when defining oxygen saturation target ranges for extremely premature infants in the first weeks of their life. It may be reasonable to keep them at lower oxygen saturation levels in order to avoid oxygen toxicity at least in this period.
The aim of oxygen therapy for extremely preterm infants beyond the first weeks of life is the prevention of a severe form of BPD along with its consequences of pulmonary hypertension, cor pulmonale or death. Supplemental oxygen can stabilize the infants' breathing pattern, support sufficient growth and weight gain, and reduce the risk of prethreshold or threshold retinopathy of prematurity. Two recent multicenter, randomized, controlled trials have provided direct evidence that keeping preterm infants at higher oxygen levels in the chronic phase of lung disease does not result in short-or long-term benefits. 10, 11 In contrast, both studies an association between higher oxygen target ranges after the first weeks of life and impaired pulmonary outcome. Keeping preterm infants after the first few weeks of life at oxygen saturation levels in the lower nineties could be a plausible consequence. However, if a patient is considered to be ready for discharge, but is not able to maintain oxygen saturation in the proposed range, domiciliary oxygen therapy should be established.
Inhaled nitric oxide in premature infants
The pathologic features of BPD include impaired lung vascular and alveolar development and an increased quantity of pulmonary arterial and airway smooth muscle. 12 Elevated pulmonary vascular resistance and trapped air lead to a ventilation-perfusion mismatch contributing to ongoing hypoxia and need for supplemental oxygen. Nitric oxide (iNO), as a selective pulmonary vasodilator, has been used extensively in term neonates with persistent pulmonary hypertension and ameliorates oxygenation and reduces the need for extracorporeal membrane oxygenation in this group of patients. 13 During the last decade, several investigators have addressed the question whether iNO is safe and effective in premature infants with different severities of respiratory failure at different postnatal ages. [14] [15] [16] [17] [18] [19] In a single-center study, preterm infants with moderate respiratory failure due to respiratory distress syndrome received either iNO, for at least 1 week, or placebo in the first week of life. The investigators found a reduction in the outcome death or BPD with the administration of iNO. 16 In a more recent multicenter trial on infants of a gestational age less than 32 weeks with moderate respiratory failure after surfactant within the first 48 hour of life, iNO did not increase the risk of BPD, intraventricular hemorrhage, necrotizing enterocolitis or patent ductus arteriosus. However, there was no difference in the primary outcome of intact survival at day of life 28 between intervention and placebo group either. 14 Three multicenter trials randomizing preterm infants to either placebo or iNO shortly after birth could not find a difference in mortality or incidence of BPD. 15, 17, 19 Post hoc subgroup analyses in the two larger studies revealed that iNO reduced the combined rate of death or BPD only for infants with a birth weight >1000 gram. 17, 19 In one study, iNO increased the incidence of BPD and severe intracranial hemorrhage for infants <1000 gram. 17 In contrast, Kinsella et al. 19 most recently found that the treatment reduced the combined end point of intracranial hemorrhage, periventricular leucomalacia, or ventriculomegaly and of periventricular leucomalacia alone.
In another large multicenter trial, infants either received a tapering dose of iNO for at least 24 days or placebo at a postnatal age of 7 to 21 days. 18 Significantly more infants in the iNO group survived to a postmenstrual age of 36 weeks without BPD compared to the placebo group. A post hoc analysis revealed that the treatment yielded a significant benefit only in the group of infants between the ages of 7 and 14 days at enrollment. 18 In summary, six randomized controlled trials have not been able to define the role of iNO in the treatment of infants at risk of BPD. In the group of extremely low birth weight (ELBW) infants with a more severe form of respiratory failure, iNO did not increase survival or reduce the incidence of BPD. Whereas, data from the three largest trials suggest that less critically ill patients might benefit from the treatment. The optimal dose, duration, time of initiation and selection of infants most likely to benefit still is unclear. Currently, published evidence does not support the use of iNO in preterm infants with respiratory failure.
20
Prophylactic vs rescue treatment with natural surfactant
The overall meta-analysis of prophylactic vs rescue treatment with natural surfactants indicates that mortality is reduced, but it does not seem to favor either strategy in the prevention of BPD. 21 However, a meta-analysis of three trials enrolling a total of 671 preterm infants treated prophylactically with the natural porcine surfactant preparation poractant-alpha (Curosurf s ; Dey L.P. Napa CA, Chiesi Farmaceutici, S.p.A., Italy) clearly demonstrated a reduction in the severity of respiratory distress syndrome, mortality and the incidence of BPD at 28 days of life. 22 Despite the limitations of this analysis, owing to the relatively small sample size, prophylactic or early surfactant treatment may have a potential role in preventing BPD, especially in preterm infants less than 28 weeks of gestational age.
Diuretics
Diuretics are frequently used in the treatment of developing or established BPD although evidence from controlled randomized trials supporting this widespread use is rather scarce. Trials included in a Cochrane Review of the effects of systemic furosemide mainly focused on short-term pathophysiologic parameters. 23 Most studies failed to assess outcomes like duration of ventilatory support, need for oxygen supplementation, length of hospital stay or mortality. In addition, evidence for a benefit concerning important clinical outcomes such as length of oxygen supplementation or development of BPD neither exists for systemic diuretics acting on the distal tubule nor for aerosolized furosemide. 24, 25 Thus, existing evidence does not support the routine or sustained use of diuretics in infants with BPD.
Methylxanthines
Methylxanthines are among the most frequently prescribed drugs in neonatal medicine. There is strong evidence that methylxanthines reduce the risk of apnea of prematurity and need for mechanical ventilation. 26 The safety of this therapy, however, is uncertain. Recently, a large multicenter trial addressed issues on the efficacy and safety of caffeine for apnea of prematurity in 2006 infants with a birth weight of 500 to 1250 g. 27 , 28 The primary purpose of this trial was to determine if the use of caffeine, beginning in the first 10 days of life, would increase the risk of death or neurosensory disability at a corrected age of 18 months. Data concerning the short-term outcome of enrolled infants before their first discharge from hospital, which have most recently been published clearly demonstrated that caffeine treatment did neither affect mortality nor the incidence of brain injury. 28 The incidence of BPD at a postmenstrual age of 36 weeks, however, was reduced from 47% in the placebo group to 36% in caffeine-treated infants (odds ratio 0.6, 95% confidence interval, 0.5 to 0.8) Similarly, the rate of drug therapy for closure of patent ductus arteriosus was reduced from 38 to 29% (odds ratio 0.67, 95% confidence interval, 0.54 to 0.82). During the first 3 weeks after randomization, infants in the caffeine group gained less weight than infants in the placebo group. No significant difference in weight gain was seen after the third week. Overall, the described findings would strongly advocate the use of caffeine in the prevention of BPD. However, assessment of the long-term effects of caffeine is needed before this therapy can be routinely recommended to prevent BPD.
Vitamin A Vitamin A is involved in the regulation of lung growth, alveolar septation, surfactant production, and supports the integrity and repair of respiratory epithelium after injury. 29 Very low birth weight (VLBW) infants often have low serum or plasma concentrations of vitamin A identified as a risk factor for the development of BPD.
30, 31 The effect of vitamin A supplementation on respiratory morbidity and mortality of VLBW infants has been assessed in several randomized controlled trials. [32] [33] [34] Results of the earlier studies were inconsistent and their interpretation hampered by small sample size and differences in patient populations, administered dose of the study drug and vitamin A dose received by the controls by either parenteral or enteral nutrition. 35 Tyson et al. 33 found a small but significant risk reduction for the outcome death or BPD, at a postmenstrual age of 36 weeks, for ELBW infants who were treated with an intramuscular dose of 5000 IU of vitamin A three times a week for the first 28 days of life in a large multicenter trial (55 vs 62%, relative risk 0.89, 95% confidence interval, 0.80 to 0.99). Wardle et al. 34 examined the effect of a daily oral dose of 5000 IU vitamin A for 28 days in ELBW infants. In their trial, the enteral administration did not significantly alter the incidence of BPD or other major outcome variables. A meta-analysis of seven trials, including those of Tyson et al. 33 and Wardle et al., 34 discovered a significant risk reduction for BPD or death at a post-natal age of 28 days for VLBW infants and a reduced risk of BPD at 36 weeks postmenstrual age for infants with a birth weight <1000 g. 35 A once-per-week intramuscular dose of 15 000 IU vitamin A in ELBW infants was discarded after a comparison with two other regimens (either 5000 or 10 000 IU three times a week) revealed that the once-per-week administration did not lead to an equivalent increase of plasma retinol levels. 36 The decision to administer repetitive intramuscular injections to ELBW infants for significant but small risk reduction should be based on a thorough evaluation of the local incidence of BPD and the potential risks of this route of administration. According to a recently published survey in the majority of level III neonatal intensive care units in the United States, this kind of therapy is not routinely used. 37 Antioxidants Oxygen toxicity plays a major role in the pathogenesis of BPD. Relative hyperoxia as well as recruitment and activation of neutrophils and macrophages in the alveoli lead to accumulation of free oxygen radicals. 38 Superoxide anions, highly reactive and destructive radicals, can be scavenged and converted into hydrogen peroxide and oxygen by superoxide dismutase (SOD). Catalase and glutathione peroxidase then catalyze the reduction of hydrogen peroxide into water. The immaturity of the intracellular enzymatic antioxidative defense and the relative lack of glutathione make preterm infants susceptible to oxidative injury, in the lung and other organs. In addition, the transferrin capacity and the ferroxidase activity are low in premature infants. The resulting predominance of free iron, in forms of the ferrous ion (Fe 2 þ ), leads to an increased production of hydroxyl radicals by the Fenton reaction. 39 Interestingly, free iron was detected in airway secretions in the vast majority of ventilated infants with BPD. 40 Currently, only two antioxidants have been evaluated for prevention or amelioration of BPD in randomized controlled trials. Ahola et al. 41 assessed the effect of a 6-day course of intravenous N-acetylcysteine (NAC) in ELBW infants. NAC is deacetylated to cysteine, the carrier of the active sulfhydryl residue in glutathione. Thus, it can replenish the intracellular glutathione stores. Three hundred and ninety-one ELBW infants who were on mechanical ventilation or continuous positive airway pressure (CPAP) by the age of 36 hour were randomized to NAC or placebo. 41 There was no effect of the drug on death or need for supplementary oxygen at 28 postnatal days or 36 postmenstrual weeks. The study drug did not ameliorate lung function parameters assessed near term in 18 of the 197 infants in the intervention group compared to 15 who had received placebo. 42 The repetitive subcutaneous administration of bovine SOD in a small randomized study in the pre-surfactant era yielded promising results. 43 In this group of relatively mature infants, SOD administration was not able to reduce the total days of oxygen therapy or mechanical ventilation but significantly reduced the days on CPAP and radiographic as well as clinical signs of BPD without major side effects. In a small study, the intratracheal application of recombinant human SOD (rhSOD) in two different dosages every 48 hours up to seven doses was well tolerated by VLBW infants and led to an increased SOD concentration in tracheal aspirate fluid and serum. 44 Neutrophil chemotactic activity was significantly reduced in tracheal aspirate samples of the two intervention groups but the trial failed to show any beneficial effect of the study drug on BPD at 28 days of life or 36 weeks postmenstrual age. In a recently published larger multicenter trial, 302 infants with birth weights of 600 to 1200 grams who were mechanically ventilated and treated with surfactant for respiratory distress syndrome were randomized to receive either intratracheal rhSOD or placebo every 48 hour up to 1 month. 45 There was no difference in the outcome BPD or death at either 28 postnatal days or 36 postmenstrual weeks between the two groups. However, until 1 year corrected age the infants treated with rhSOD needed less asthma medications to treat significant respiratory disorder than those in the control group. The difference was even more pronounced for infants with a gestational age <27 weeks. In this subset of patients, rhSOD also led to a lower rate of hospitalization and emergency room visits by the time of follow-up. These data suggest that antioxidant therapy might attenuate long-term pulmonary disease in the group of infants at highest risk. 45 However, this finding has to be confirmed in future trials.
Anti-inflammatory strategies
Proteolytic enzymes released by inflammatory cells in the lung play a pivotal role in the initiation of epithelial injury and lung remodeling leading to BPD. Activated neutrophil granulocytes release elastase into the airways, 46 a serine proteinase, which is capable of degrading a variety of extracellular matrix proteins. The action of elastase is usually counterbalanced by forming a complex with a1-proteinase inhibitor (a1-PI), a glycoprotein synthesized by the liver. Premature infants have very low levels of active a1-PI, probably because of oxidative inactivation of the inhibitor. 47 The imbalance between neutrophil elastase and its naturally occurring inhibitor cannot be influenced exclusively by decreasing the release of the protease. The effects of a1-PI in preterm infants have been assessed in two randomized controlled trials. 48, 49 In the first study, infants with a birth weight <1250 g were either randomized to four doses of intravenous a1-PI or placebo in the first 2 weeks of life. 49 In the second trial, the same investigators compared three different dose regimens to placebo. 48 A metaanalysis of these studies revealed a significant risk reduction for oxygen dependency at 28 days postnatal age when any doses of a1-PI were combined, but failed to reveal any benefit with regards to BPD at 36 weeks postmenstrual age or other respiratory parameters like duration of oxygen support. 50 Another anti-inflammatory strategy to prevent BPD has recently been suggested. Clara Cell 10kD protein (CC10) is the major secretory product of Clara cells in human lungs, which in vitro inhibits the soluble phospholipase A2. 51 As a potent antiinflammatory agent, it seems to play an important role in the innate immune system. In a small randomized trial, two different dose regimens of a single intratracheal dose of recombinant human CC10 in ventilated infants less than 1300 grams were compared to placebo. 52 The study drug was well tolerated and led to a significant reduction of tracheal aspirate neutrophil counts and protein concentrations as markers of pulmonary inflammation and damage to the alveolar-capillary integrity during the first 3 days of life. The trial was not powered to show any effect on BPD. The potential effects of this specific anti-inflammatory drug on the development of the disease and the issue of optimal dosing regimens must be addressed by randomized trials.
Corticosteroids
Three meta-analyses of randomized controlled trials have assessed the influence of early, moderately early and late systemic corticosteroid administration in the prevention of BPD. [53] [54] [55] Briefly, systemic corticosteroids can reduce the risk for BPD at either 28 days of life or 36 weeks postmenstrual age without affecting mortality. In face of the potential short-and long-term adverse effects -especially with those of early administration on the increased risk of cerebral palsy -they should be restricted to the severest cases of BPD with a high risk of death from respiratory failure. 56 Currently, there is no evidence that early inhaled corticosteroids confer important advantages over systemic steroids in the prevention of BPD. 57, 58 Future investigations are warranted assessing benefit and harm of steroid 'substitution' in groups of infants whose cortisol levels are low. 59 Ureaplasma urealyticum and erythromycin Ureaplasma urealyticum (U. urealyticum) and its association with BPD has remained controversial for almost the last two decades although numerous studies have focused on this issue. Comparison of these studies has been hampered by differences in patient selection, sampling and culture methods, and definition of BPD. A recent meta-analysis of 23 observational studies including 2216 infants underlined the association of U. urealyticum with an increased risk of BPD at either day of life 28 or 36 weeks' postmenstrual age. 60 However, the authors found a significant inter-study variance of the effect size with the greatest reported effects in the earlier and smaller studies. In a prospective longitudinal single-center study, only a pattern of persistent U. urealyticum colonization for weeks was associated with BPD. 61 This finding made the authors speculate that persistent colonization with the pathogen might result in ongoing cytokine production leading to prolonged inflammation and lung injury. Indeed, preterm infants whose airways were colonized with U. urealyticum showed a relevant inflammatory response in their airways. 62 The question whether early administration of erythromycin can influence this airway inflammation and reduce the incidence of BPD has been addressed by two small randomized trials. 63, 64 Both trials included infants less than 30 weeks gestational age who were mechanically ventilated. They were not able to demonstrate an effect of erythromycin treatment on the development of BPD at 36 weeks postmenstrual age. However, a true benefit might easily have been missed because of the small sample sizes. Moreover, we cannot exclude the possibility that a considerable number of preterm infants may have been infected with U. urealyticum in utero, and may be born with inflamed and injured lungs. Post-natal erythromycin treatment may, therefore, be a rather late intervention, which may not be able to interfere with the ongoing pulmonary inflammatory process. 2 Thus, a definite conclusion regarding the effect of erythromycin on the development of BPD cannot be drawn without additional evidence from an optimally timed randomized trial. 65 Conclusions Many strategies to prevent or ameliorate BPD have been evaluated so far (Table 1, Figure 1 ). Evidence for a long-term preventive effect exists for the repetitive intramuscular administration of high doses of vitamin A. Oxygen supplementation remains an important therapeutic strategy for patients with established BPD. Targeting the infants at lower oxygen saturation seems to reduce long-term pulmonary morbidity without significantly increasing the risk of adverse neurosensory outcome. In addition, prophylactic or very early surfactant administration in very immature infants may have a beneficial effect on the incidence of BPD. Currently, there is no sufficient evidence for a routine use of iNO for the prevention of the disease. However, iNO can ameliorate oxygenation in premature infants with severe respiratory failure and might be useful in selected patients with BPD and severe pulmonary hypertension. A temporary use of diuretics can improve lung function and oxygenation in these infants. Nonetheless, existing data do not justify a sustained diuretic therapy. Meta-analyses of observational studies favor a role of U. urealyticum in the pathogenesis of BPD. However, interpretation of results from trials of erythromycin in the prevention of the disease is hampered by small sample sizes. Definite assessment of long-term neurosensory outcome is pending, routine use can currently not be recommended. 28 d Effect has only been described for one natural surfactant. 22 As the pathogenesis of disturbed alveolarization, vascularization and tissue repair in the immature lung leading to BPD is multifactorial, it is unlikely that one single agent will be identified as a 'miracle drug' in the prevention or treatment of the disease. The 'miracle drug' of the 1990s, dexamethasone, has almost completely lost its role in the management of extremely premature infants. SOD and a1-PI have not proved to reduce the risk of moderate or severe BPD yet. Effects of other anti-inflammatory substances like intratracheal CC10 still have to be assessed in detail. The early administration of caffeine for prophylaxis and treatment of apnea of prematurity has most recently been shown to reduce the risk of BPD. This finding is surprising and promising at the same time. However, the definite assessment of the primary outcome of the caffeine trial is needed before its routine use can be recommended for the prevention of BPD.
